Perlmutter Cancer Center opens transplantation and cellular therapy center for blood cancers

Drug in clinical trials for breast cancer could also treat some blood cancers, studies show

Two new studies led by researchers at Washington University School of Medicine in St. Louis have identified a possible way to block the progression of several forms of blood cancer using a drug already in clinical trials against breast cancer.

January 17, 2025

Vol.51 No.02

Clinical Roundup

UTSW scientists link hematopoietic cell transplant deaths to beta-blocker use

Patients can die if they take certain previously prescribed beta-blockers during a hematopoietic cell transplant due to suppressed signals from nerves that promote bone marrow regeneration, according to scientists at the Children’s Medical Center Research Institute at UT Southwestern, published in Cancer Discovery, builds upon previous CRI research by analyzing retrospective patient data to correlate beta-blocker use with significantly worse patient outcomes.

January 10, 2025

Vol.51 No.01

Clinical Roundup

Cell donor’s socioeconomic status shapes cancer treatment outcomes

The socioeconomic status of cell donors affects the health outcomes of blood cancer patients who underwent hematopoietic cell transplantation, according to a new study led by researchers at the University of Minnesota Medical School.

July 19, 2024

Vol.50 No.29

Clinical Roundup

Mayo Clinic performs world’s first known successful total larynx transplant in a patient with active cancer

A multidisciplinary team of doctors at Mayo Clinic in Arizona performed the third known total larynx transplant in the U.S.

July 12, 2024

Vol.50 No.28

Drugs & Targets

Estonia to develop personalized CAR T-cell therapy for blood cancer patients

The Tartu University Hospital, North Estonia Medical Centre, and Icosagen have joined forces to develop and introduce an innovative personalized cell therapy for patients in Estonia.

May 31, 2024

Vol.50 No.22

Clinical Roundup

Cyclophosphamide may expand transplant donor pool for patients with blood cancers

A new treatment approach using an older drug may enable more patients with high-risk blood cancers to receive transplanted stem cells from unrelated, partially matched donors, according to a study conducted by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and colleagues.

May 24, 2024

Vol.50 No.21

Perlmutter Cancer Center opens transplantation and cellular therapy center for blood cancers

YOU MAY BE INTERESTED IN

Drug in clinical trials for breast cancer could also treat some blood cancers, studies show

UTSW scientists link hematopoietic cell transplant deaths to beta-blocker use

Cell donor’s socioeconomic status shapes cancer treatment outcomes

Mayo Clinic performs world’s first known successful total larynx transplant in a patient with active cancer

Estonia to develop personalized CAR T-cell therapy for blood cancer patients

Cyclophosphamide may expand transplant donor pool for patients with blood cancers

Renew today!

Subscriber content

Never miss an issue!

Login